Last reviewed · How we verify
Daclatasvir plus Asunaprevir
Daclatasvir and asunaprevir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS3 protease, respectively, blocking viral replication.
Daclatasvir and asunaprevir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS3 protease, respectively, blocking viral replication. Used for Chronic hepatitis C virus infection (genotype 1b).
At a glance
| Generic name | Daclatasvir plus Asunaprevir |
|---|---|
| Sponsor | Myeong Jun Song |
| Drug class | Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor) |
| Target | HCV NS5A protein and HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease (Hepatology) |
| Phase | FDA-approved |
Mechanism of action
Daclatasvir is an NS5A inhibitor that disrupts hepatitis C virus replication and assembly, while asunaprevir is an NS3/4A protease inhibitor that prevents cleavage of viral polyproteins necessary for viral maturation. Together, this combination targets two distinct steps in the HCV life cycle, reducing the likelihood of resistance development.
Approved indications
- Chronic hepatitis C virus infection (genotype 1b)
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (PHASE3)
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)
- Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection (PHASE2)
- Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daclatasvir plus Asunaprevir CI brief — competitive landscape report
- Daclatasvir plus Asunaprevir updates RSS · CI watch RSS
- Myeong Jun Song portfolio CI